These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 1783430)
1. Defined chemically cross-linked oligomers of human C-reactive protein: characterization and reactivity with the complement system. Jiang H; Lint TF; Gewurz H Immunology; 1991 Dec; 74(4):725-31. PubMed ID: 1783430 [TBL] [Abstract][Full Text] [Related]
2. Binding and complement activation by C-reactive protein via the collagen-like region of C1q and inhibition of these reactions by monoclonal antibodies to C-reactive protein and C1q. Jiang HX; Siegel JN; Gewurz H J Immunol; 1991 Apr; 146(7):2324-30. PubMed ID: 2005402 [TBL] [Abstract][Full Text] [Related]
3. Solid-phase classical complement activation by C-reactive protein (CRP) is inhibited by fluid-phase CRP-C1q interaction. Sjöwall C; Wetterö J; Bengtsson T; Askendal A; Almroth G; Skogh T; Tengvall P Biochem Biophys Res Commun; 2007 Jan; 352(1):251-8. PubMed ID: 17113035 [TBL] [Abstract][Full Text] [Related]
4. Studies on the interactions between C-reactive protein and complement proteins. Bíró A; Rovó Z; Papp D; Cervenak L; Varga L; Füst G; Thielens NM; Arlaud GJ; Prohászka Z Immunology; 2007 May; 121(1):40-50. PubMed ID: 17244159 [TBL] [Abstract][Full Text] [Related]
5. Human serum amyloid P component oligomers bind and activate the classical complement pathway via residues 14-26 and 76-92 of the A chain collagen-like region of C1q. Ying SC; Gewurz AT; Jiang H; Gewurz H J Immunol; 1993 Jan; 150(1):169-76. PubMed ID: 8417122 [TBL] [Abstract][Full Text] [Related]
6. Effect of modified C-reactive protein on complement activation: a possible complement regulatory role of modified or monomeric C-reactive protein in atherosclerotic lesions. Ji SR; Wu Y; Potempa LA; Liang YH; Zhao J Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):935-41. PubMed ID: 16456095 [TBL] [Abstract][Full Text] [Related]
7. Probing the C1q-binding site on human C-reactive protein by site-directed mutagenesis. Agrawal A; Volanakis JE J Immunol; 1994 Jun; 152(11):5404-10. PubMed ID: 8189060 [TBL] [Abstract][Full Text] [Related]
8. Serum amyloid P component binds to histones and activates the classical complement pathway. Hicks PS; Saunero-Nava L; Du Clos TW; Mold C J Immunol; 1992 Dec; 149(11):3689-94. PubMed ID: 1431140 [TBL] [Abstract][Full Text] [Related]
9. Specific inhibition of the classical complement pathway with an engineered single-chain Fv to C1q globular heads decreases complement activation by apoptotic cells. Duvall MR; Hwang HY; Boackle RJ Immunobiology; 2010 May; 215(5):395-405. PubMed ID: 19586684 [TBL] [Abstract][Full Text] [Related]
10. Characterization and isolation of a C-reactive protein receptor from the human monocytic cell line U-937. Tebo JM; Mortensen RF J Immunol; 1990 Jan; 144(1):231-8. PubMed ID: 2153164 [TBL] [Abstract][Full Text] [Related]
11. Binding of C-reactive protein to nucleated cells leads to complement activation without cytolysis. Berman S; Gewurz H; Mold C J Immunol; 1986 Feb; 136(4):1354-9. PubMed ID: 3944459 [TBL] [Abstract][Full Text] [Related]
12. Localization of sites through which C-reactive protein binds and activates complement to residues 14-26 and 76-92 of the human C1q A chain. Jiang H; Robey FA; Gewurz H J Exp Med; 1992 May; 175(5):1373-9. PubMed ID: 1569403 [TBL] [Abstract][Full Text] [Related]
13. Binding of the pentamer/hexamer forms of mannan-binding protein to zymosan activates the proenzyme C1r2C1s2 complex, of the classical pathway of complement, without involvement of C1q. Lu JH; Thiel S; Wiedemann H; Timpl R; Reid KB J Immunol; 1990 Mar; 144(6):2287-94. PubMed ID: 2313094 [TBL] [Abstract][Full Text] [Related]
14. Native, amyloid fibrils and beta-oligomers of the C-terminal domain of human prion protein display differential activation of complement and bind C1q, factor H and C4b-binding protein directly. Sjöberg AP; Nyström S; Hammarström P; Blom AM Mol Immunol; 2008 Jun; 45(11):3213-21. PubMed ID: 18406463 [TBL] [Abstract][Full Text] [Related]
15. Structure and function of the long pentraxin PTX3 glycosidic moiety: fine-tuning of the interaction with C1q and complement activation. Inforzato A; Peri G; Doni A; Garlanda C; Mantovani A; Bastone A; Carpentieri A; Amoresano A; Pucci P; Roos A; Daha MR; Vincenti S; Gallo G; Carminati P; De Santis R; Salvatori G Biochemistry; 2006 Sep; 45(38):11540-51. PubMed ID: 16981714 [TBL] [Abstract][Full Text] [Related]
16. Requirements for the binding of human plasma fibronectin to the C1q subunit of the first component of complement. Sorvillo J; Gigli I; Pearlstein E J Immunol; 1983 Sep; 131(3):1400-4. PubMed ID: 6309962 [TBL] [Abstract][Full Text] [Related]
17. Identification and partial characterization of multiple native and neoantigenic epitopes of human C-reactive protein by using monoclonal antibodies. Ying SC; Gewurz H; Kinoshita CM; Potempa LA; Siegel JN J Immunol; 1989 Jul; 143(1):221-8. PubMed ID: 2471736 [TBL] [Abstract][Full Text] [Related]
18. Sphingomyelinases D induce direct association of C1q to the erythrocyte membrane causing complement mediated autologous haemolysis. Tambourgi DV; Pedrosa MF; de Andrade RM; Billington SJ; Griffiths M; van den Berg CW Mol Immunol; 2007 Jan; 44(4):576-82. PubMed ID: 16540172 [TBL] [Abstract][Full Text] [Related]
19. Complement C1q-target proteins recognition is inhibited by electric moment effectors. Roumenina L; Bureeva S; Kantardjiev A; Karlinsky D; Andia-Pravdivy JE; Sim R; Kaplun A; Popov M; Kishore U; Atanasov B J Mol Recognit; 2007; 20(5):405-15. PubMed ID: 17929239 [TBL] [Abstract][Full Text] [Related]
20. Absence of a binding reactivity of human C-reactive protein for immunoglobulin or immune complexes. Ballou SP; Macintyre SS J Lab Clin Med; 1990 Mar; 115(3):332-8. PubMed ID: 2107267 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]